Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00383188
Registration number
NCT00383188
Ethics application status
Date submitted
28/09/2006
Date registered
2/10/2006
Date last updated
20/08/2021
Titles & IDs
Public title
An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis
Query!
Scientific title
A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF PH 797804, ADMINISTERED ORALLY ONCE DAILY IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS
Query!
Secondary ID [1]
0
0
2006-003577-27
Query!
Secondary ID [2]
0
0
A6631007
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - placebo
Treatment: Drugs - PH-797804
Treatment: Drugs - PH-797804
Treatment: Drugs - PH-797804
Treatment: Drugs - PH-797804
Placebo Comparator: 1 -
Experimental: 2 -
Experimental: 3 -
Experimental: 4 -
Experimental: 5 -
Treatment: Drugs: placebo
Capsule, once daily (QD) for 12 weeks
Treatment: Drugs: PH-797804
Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
Treatment: Drugs: PH-797804
Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
Treatment: Drugs: PH-797804
Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
Treatment: Drugs: PH-797804
Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving American College of Rheumatology 20 Percent (%) (ACR 20) Response at Week 12
Query!
Assessment method [1]
0
0
ACR20 responders: participants with greater than or equal to(>=)20% improvement in tender and swollen 28-joint counts from baseline, >=20% improvement in at least 3 of 5 measures: Patient's global assessment of arthritis(PGA), physician's global assessment of arthritis, participant's assessment of pain on visual analogue scale (Pain-VAS), health assessment questionnaire-disability index (HAQ-DI), C-reactive protein (CRP) in mg/liter (mg/L). PGA:participant assess overall disease activity on VAS, score:0(no arthritis) to 100(extreme arthritis), high score=more arthritis. Physician's global assessment:physician judge participant's overall disease activity on VAS, score:0(no arthritis) to 100millimeter(mm) (extreme arthritis), high score=more arthritis. Pain-VAS:participant assess arthritis pain on 100mm VAS, score:0mm (no pain) to 100mm (extreme pain), high score=more pain. HAQ-DI:functional disability evaluation, score:0 (no difficulty) to 3 (unable to do), high score=more disability.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving American College of Rheumatology 20 Percent (%) (ACR 20) Response at Weeks 1, 2, 4, 8 and 16
Query!
Assessment method [1]
0
0
ACR20 responders: participants with greater than or equal to(>=)20% improvement in tender and swollen 28-joint counts from baseline, >=20% improvement in at least 3 of 5 measures: Patient's global assessment of arthritis(PGA), physician's global assessment of arthritis, participant's assessment of pain on visual analogue scale (Pain-VAS), health assessment questionnaire-disability index (HAQ-DI), C-reactive protein (CRP) in mg/L. PGA:participant assess overall disease activity on VAS, score:0(no arthritis) to 100(extreme arthritis), high score=more arthritis. Physician's global assessment:physician judge participant's overall disease activity on VAS, score:0(no arthritis) to 100millimeter(mm) (extreme arthritis), high score=more arthritis. Pain-VAS:participant assessed arthritis pain on 100mm VAS, score:0mm (no pain) to 100mm (extreme pain), high score=more pain. HAQ-DI:functional disability evaluation, score:0 (no difficulty) to 3 (unable to do), high score=more disability.
Query!
Timepoint [1]
0
0
Weeks 1, 2, 4, 8, 16
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving American College of Rheumatology 50 Percent (%) (ACR 50) Response at Weeks 1, 2, 4, 8, 12 and 16
Query!
Assessment method [2]
0
0
ACR50 responders: participants with >= 50% improvement in tender and swollen 28-joint counts from baseline and >= 50% improvement in at least 3 of the 5 measures: PGA, physician global assessment, Pain-VAS, HAQ-DI and C-reactive protein (in mg/L). PGA: participant assessed overall disease activity on VAS, score: 0 (no arthritis) to 100 (extreme arthritis), higher score=more arthritis. Physician global assessment: physician judged participant's overall disease activity on VAS, score: 0 (no arthritis) to 100 mm VAS (extreme arthritis), higher score=more arthritis. Pain-VAS: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (extreme pain), higher score=more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.
Query!
Timepoint [2]
0
0
Weeks 1, 2, 4, 8, 12 and 16
Query!
Secondary outcome [3]
0
0
Percentage of Participants Achieving American College of Rheumatology 70 Percent (%) (ACR 70) Response at Weeks 1, 2, 4, 8, 12 and 16
Query!
Assessment method [3]
0
0
ACR70 responders: participants with >=70% improvement in tender and swollen 28-joint counts from baseline and >= 70% improvement in at least 3 of the 5 measures: PGA, physician global assessment, Pain-VAS, HAQ-DI and CRP (in mg/L). PGA: participant assessed overall disease activity on VAS, score: 0 (no arthritis) to 100 (extreme arthritis), higher score=more arthritis. Physician global assessment: physician judged participant's overall disease activity on VAS, score: 0 (no arthritis) to 100 mm VAS (extreme arthritis), higher score=more arthritis. Pain-VAS: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (extreme pain), higher score=more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.
Query!
Timepoint [3]
0
0
Weeks 1, 2, 4, 8, 12 and 16
Query!
Secondary outcome [4]
0
0
Change From Baseline in Tender/Painful Joint Count at Weeks 1, 2, 4, 8, 12 and 16
Query!
Assessment method [4]
0
0
A total of 28 tender/painful joints were assessed for tenderness or pain. The 28 joints included: shoulders, elbows, wrists, metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and knees. Artificial joints were not assessed.
Query!
Timepoint [4]
0
0
Baseline, Weeks 1, 2, 4, 8, 12 and 16
Query!
Secondary outcome [5]
0
0
Change From Baseline in Swollen Joint Count at Weeks 1, 2, 4, 8, 12 and 16
Query!
Assessment method [5]
0
0
A total of 28 swollen joints were assessed. The 28 joints included: shoulders, elbows, wrists, MCP joints, PIP joints, and knees. Artificial joints were not assessed.
Query!
Timepoint [5]
0
0
Baseline, Weeks 1, 2, 4, 8, 12 and 16
Query!
Secondary outcome [6]
0
0
Change From Baseline in Participant Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, 12 and 16
Query!
Assessment method [6]
0
0
Participants self-assessed the severity of arthritis pain using a 100 mm VAS between 0 mm (no pain) and 100 mm (most severe pain), where higher scores indicate higher degree of pain intensity.
Query!
Timepoint [6]
0
0
Baseline, Weeks 1, 2, 4, 8, 12 and 16
Query!
Secondary outcome [7]
0
0
Change From Baseline in Participant Global Assessment (PGA) of Arthritis at Weeks 1, 2, 4, 8 12 and 16
Query!
Assessment method [7]
0
0
Participants responded to the question "Considering all the ways your arthritis affects you, how are you feeling today?" was recorded using a 0-100 mm VAS where 0 mm (very well) and 100 mm (very poor). Higher scores indicated worse condition.
Query!
Timepoint [7]
0
0
Baseline, Week 1, 2, 4, 8, 12 and 16
Query!
Secondary outcome [8]
0
0
Change From Baseline in Physician Global Assessment of Arthritis at Weeks 1, 2, 4, 8, 12 and 16
Query!
Assessment method [8]
0
0
Physician assessed the overall impact of arthritis on the participants' daily life based on the disease signs, functional capacity and physical examination. The physician's response was recorded using a 100 mm VAS between 0 mm (very good) and 100 mm (very poor). Higher scores indicating worse condition of arthritis.
Query!
Timepoint [8]
0
0
Baseline, Week 1, 2, 4, 8, 12 and 16
Query!
Secondary outcome [9]
0
0
Change From Baseline in C-Reactive Protein (CRP) at Weeks 1, 2, 4, 8, 12 and 16
Query!
Assessment method [9]
0
0
C-reactive protein is a biochemical measure of inflammation and disease activity.
Query!
Timepoint [9]
0
0
Baseline, Week 1, 2, 4, 8, 12 and 16
Query!
Secondary outcome [10]
0
0
Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4 [CRP]) at Weeks 1, 2, 4, 8, 12 and 16
Query!
Assessment method [10]
0
0
DAS28-4 (CRP) was calculated from 28-tender joint count and 28-swollen joint count, C-reactive protein (mg/L) and PGA : participant assessed overall disease activity on VAS, score:0(no arthritis) to 100(extreme arthritis). DAS28-4 (CRP) lower than (<) 3.2 implied mild disease activity, 3.2 to 5.1 implied moderate disease activity and greater than (>) 5.1 severe disease activity. Total score range: 0 to 9.4, higher score indicated more disease activity.
Query!
Timepoint [10]
0
0
Baseline, Weeks 1, 2, 4, 8, 12 and 16
Query!
Secondary outcome [11]
0
0
Number of Participants Who Withdrew From Study Due to Lack of Efficacy
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Baseline up to Week 16
Query!
Secondary outcome [12]
0
0
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Weeks 1, 2, 4, 8, 12 and 16
Query!
Assessment method [12]
0
0
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing/grooming, arising, eating, walking, reaching, gripping, hygiene, and "other common activities" over past week. Each item scored on 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total average possible score range 0 (least difficulty) to 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
Query!
Timepoint [12]
0
0
Baseline, Week 1, 2, 4, 8, 12 and 16
Query!
Secondary outcome [13]
0
0
Change From Baseline in Modified Brief Pain Inventory-Short Form (mBPI-SF) Score at Weeks 1, 2, 4, 8 and 12
Query!
Assessment method [13]
0
0
The modified brief pain inventory-short form (mBPI-SF) is a pain assessment tool used to measure both pain intensity and pain interference using an 11-point numeric rating scale. Participants rated their pain severity, using a scale from 0 (no pain) to 10 (pain as bad as you can imagine), where higher scores indicate greater intensity of pain. Participants also rated the level of pain interference using a scale from 0 (no interference) to 10 (complete interference), where higher scores indicate more degree of interference in general daily activities.
Query!
Timepoint [13]
0
0
Baseline, Week 1, 2, 4, 8 and 12
Query!
Secondary outcome [14]
0
0
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2 at Weeks 4 and 12
Query!
Assessment method [14]
0
0
The SF-36 version 2 is a 36-item generic health status measure standardized survey is a standardized survey evaluating 8 domains of functional health and well-being: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE) and mental health (MH). The summary score of these concepts is summarized as Physical component summary (PCS) score and Mental component summary (MCS) score, are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH. The score for each of 8 domains were scaled from 0 (lowest level of functioning) to100 (highest level of functioning, where higher scores represented better level of functioning. 8 domains were summarized as 2 summary scores; PCS and MCS. Score range for each of the 2 summary scores = 0 (lowest level of functioning) to 100 (highest level of functioning), where higher scores represented better level of functioning.
Query!
Timepoint [14]
0
0
Baseline, Weeks 4, 12
Query!
Secondary outcome [15]
0
0
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [15]
0
0
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events are events between first dose of study drug and up to week 16 after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.
Query!
Timepoint [15]
0
0
Baseline up to Week 16
Query!
Secondary outcome [16]
0
0
Number of Participants With Laboratory Abnormalities
Query!
Assessment method [16]
0
0
Haemoglobin, haematocrit, red blood cell count less than(<) 0.8*lower limit of normal [LLN], platelets <0.5*LLN and (&) greater than(>) 1.75*ULN, white blood cell count <0.6*LLN&>1.5x ULN, lymphocytes <0.8*LLN&>1.2*ULN, total neutrophils <0.8*LLN&>1.2*ULN, basophils, eosinophils, monocytes >1.2*ULN; total bilirubin >1.5*ULN, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, alkaline phosphatase >3.0*ULN, total protein <0.8*LLN&>1.2*ULN, albumin <0.8*LLN&>1.2*ULN; blood urea nitrogen, Creatinine, Uric Acid >1.2*ULN; Cholesterol >1.3*ULN, HDL Cholesterol <0.8*LLN, LDL Cholesterol >1.2*ULN, Triglycerides >1.3*ULN; Electrolytes: sodium <0.95*LLN&>1.05*ULN, potassium <0.9*LLN&>1.1*ULN, chloride, calcium, magnesium, bicarbonate <0.9*LLN&>1.1*ULN, phosphate <0.8*LLN&>1.2x ULN; glucose <0.6*LLN&>1.5*ULN, human chorionic gonadotrophin >0; CRP >1.25*ULN, ([urine-RBC, WBC, epithelial cells, crystals, yeast cells] >=6), urine casts >1, urine Bacteria >20.
Query!
Timepoint [16]
0
0
Baseline up to Week 16
Query!
Secondary outcome [17]
0
0
Number of Participants With Clinically Significant Vital Signs Abnormalities
Query!
Assessment method [17]
0
0
Pre-defined criteria for vital sign abnormalities: Maximum (max) increase from baseline in supine systolic blood pressure (SBP) >=30 milliliters of mercury (mmHg), maximum increase from baseline in supine diastolic blood pressure (DBP) >=20 mmHg.
Query!
Timepoint [17]
0
0
Baseline up to Week 16
Query!
Secondary outcome [18]
0
0
Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Parameters
Query!
Assessment method [18]
0
0
12-lead ECG were performed after the participant had rested quietly for at least 10 minutes in a supine position. ECG parameters included RR interval, PR interval, QRS complex, QT interval, corrected QT (QTc) interval, Bazett's correction QT (QTcB) interval, Heart Rate and Fridericia's correction (QTcF) interval. Clinical significance of 12-Lead ECG was judged by investigator.
Query!
Timepoint [18]
0
0
Baseline up to Week 16
Query!
Secondary outcome [19]
0
0
Number of Participants With Electrocardiogram (ECG) Abnormalities
Query!
Assessment method [19]
0
0
Criteria for ECG abnormalities: maximum QT interval (millisecond [msec]): < 450, 450 to <480, 480 to <500, >= 500; maximum QT interval with Bazett's correction (QTcB interval) (msec): <450, 450 to <480, 480 to <500, >=500; maximum QT interval with Fridericia's correction (QTcF interval) (msec): <450, 450 to <480, 480 to <500, >=500; maximum QTc interval increase from baseline (msec): change <30, 30 <=change <60, change >=60.
Query!
Timepoint [19]
0
0
Baseline up to Week 16
Query!
Secondary outcome [20]
0
0
Number of Participants With Clinically Significant Physical Examination Abnormalities
Query!
Assessment method [20]
0
0
Following criteria and body systems were examined to identify the clinically significant physical examination abnormalities; general appearance, skin (presence of rash), head, ears, eyes, nose, and throat, lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs, peripheral edema), abdominal (palpation and auscultation), neurologic (mental status, station, gait, reflexes, motor and sensory function, coordination). Physical examination abnormalities were as determined by the investigator.
Query!
Timepoint [20]
0
0
Baseline up to Week 16
Query!
Secondary outcome [21]
0
0
Minimum Observed Plasma Pre-dose Concentration (Ctrough Min) of Steady State
Query!
Assessment method [21]
0
0
Query!
Timepoint [21]
0
0
Predose
Query!
Secondary outcome [22]
0
0
Number of Participants With Concomitant Medications
Query!
Assessment method [22]
0
0
Concomitant medication (any medication other than, and in addition to, the study medication) taken for any period of time during the study and was coded by World Health Organization (WHO) medical dictionary.
Query!
Timepoint [22]
0
0
Baseline up to Week 16
Query!
Eligibility
Key inclusion criteria
- Diagnosed with RA and has failed at least 1 DMARD therapy
Query!
Minimum age
19
Years
Query!
Query!
Maximum age
90
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Any other inflammatory arthritis and any significant history of acute or chronic
infection with immunomodulatory etiology.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/12/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/07/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
305
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Emeritus Research - Malvern East
Query!
Recruitment postcode(s) [1]
0
0
3145 - Malvern East
Query!
Recruitment outside Australia
Country [1]
0
0
Brazil
Query!
State/province [1]
0
0
Paraná
Query!
Country [2]
0
0
Brazil
Query!
State/province [2]
0
0
PR
Query!
Country [3]
0
0
Brazil
Query!
State/province [3]
0
0
SP
Query!
Country [4]
0
0
Chile
Query!
State/province [4]
0
0
RM
Query!
Country [5]
0
0
Chile
Query!
State/province [5]
0
0
V Region
Query!
Country [6]
0
0
Chile
Query!
State/province [6]
0
0
VI Región
Query!
Country [7]
0
0
Czechia
Query!
State/province [7]
0
0
Brno
Query!
Country [8]
0
0
Czechia
Query!
State/province [8]
0
0
Olomouc
Query!
Country [9]
0
0
Czechia
Query!
State/province [9]
0
0
Ostrava - Trebovice
Query!
Country [10]
0
0
Czechia
Query!
State/province [10]
0
0
Praha 2
Query!
Country [11]
0
0
Czechia
Query!
State/province [11]
0
0
Praha 4
Query!
Country [12]
0
0
Czechia
Query!
State/province [12]
0
0
Zlin
Query!
Country [13]
0
0
Estonia
Query!
State/province [13]
0
0
Tallinn
Query!
Country [14]
0
0
India
Query!
State/province [14]
0
0
Andhra Pradesh
Query!
Country [15]
0
0
India
Query!
State/province [15]
0
0
Karnataka
Query!
Country [16]
0
0
India
Query!
State/province [16]
0
0
Maharashtra
Query!
Country [17]
0
0
India
Query!
State/province [17]
0
0
Punjab
Query!
Country [18]
0
0
India
Query!
State/province [18]
0
0
Tamil NADU
Query!
Country [19]
0
0
Korea, Republic of
Query!
State/province [19]
0
0
Anyang
Query!
Country [20]
0
0
Korea, Republic of
Query!
State/province [20]
0
0
Seoul
Query!
Country [21]
0
0
Peru
Query!
State/province [21]
0
0
Lima
Query!
Country [22]
0
0
Poland
Query!
State/province [22]
0
0
Bialystok
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Poznan
Query!
Country [24]
0
0
Poland
Query!
State/province [24]
0
0
Warszawa
Query!
Country [25]
0
0
Russian Federation
Query!
State/province [25]
0
0
Moscow
Query!
Country [26]
0
0
Russian Federation
Query!
State/province [26]
0
0
Smolensk
Query!
Country [27]
0
0
Russian Federation
Query!
State/province [27]
0
0
St. Petersburg
Query!
Country [28]
0
0
South Africa
Query!
State/province [28]
0
0
Gauteng
Query!
Country [29]
0
0
South Africa
Query!
State/province [29]
0
0
Johannesburg
Query!
Country [30]
0
0
South Africa
Query!
State/province [30]
0
0
Bloemfontein
Query!
Country [31]
0
0
South Africa
Query!
State/province [31]
0
0
Durban
Query!
Country [32]
0
0
South Africa
Query!
State/province [32]
0
0
Kempton Park
Query!
Country [33]
0
0
South Africa
Query!
State/province [33]
0
0
Pretoria
Query!
Country [34]
0
0
Spain
Query!
State/province [34]
0
0
Vizcaya
Query!
Country [35]
0
0
Spain
Query!
State/province [35]
0
0
Sevilla
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Investigating the safety and tolerability of a p38 inhibitor as monotherapy in subjects who
have failed at least 1 DMARD.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00383188
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00383188
Download to PDF